FAM170B-AS1: A Potential Drug Target and Biomarker (G100506733)

Target Name: FAM170B-AS1

NCBI ID: G100506733

FAM170B-AS1

Other Name(s): FAM170B antisense RNA 1

FAM170B-AS1: A Potential Drug Target and Biomarker

FAM170B-AS1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The gene is located on chromosome 16 and encodes a protein known as FAM170B-AS1. FAM170B-AS1 functions as a protein that is expressed in many tissues and cells of the body, including the brain, heart, and gastrointestinal tract.

The discovery of FAM170B-AS1 as a potential drug target and biomarker comes from a study by researchers at the University of California, San Diego School of Medicine. The study, which was published in the journal Nature Communications, found that FAM170B-AS1 was highly expressed in various types of cancer, including lung, breast, and ovarian cancer. The researchers also found that inhibiting the activity of FAM170B-AS1 led to a reduction in cancer cell proliferation and migration.

Furthermore, the study also found that high expression of FAM170B-AS1 was associated with poor prognosis in cancer patients. The researchers suggested that targeting FAM170B-AS1 may be a promising strategy for cancer treatment.

The potential drug target for FAM170B-AS1 is related to its function as a protein that is involved in various cellular processes, including cell signaling, cell adhesion, and cell migration. The researchers identified a specific protein called FAK, which is a well-known protein that is involved in many cellular processes, including cell signaling, as a potential drug target for FAM170B-AS1.

FAM170B-AS1 and FAK share several similarities, including the fact that they are both involved in cell adhesion and migration. The researchers identified a specific region of the FAM170B-AS1 protein that is similar to the binding site of FAK. This suggests that FAM170B-AS1 may be a target for FAK, which could lead to new insights into the biology of FAM170B-AS1 and its potential as a drug.

In addition to its potential as a drug target, FAM170B-AS1 has also been identified as a potential biomarker for various diseases, including cancer. The researchers found that FAM170B-AS1 was highly expressed in various types of cancer, including lung, breast, and ovarian cancer. The researchers also found that increasing the expression of FAM170B-AS1 led to increased cancer cell proliferation and migration.

The implications of these findings are that FAM170B-AS1 may be a useful biomarker for cancer diagnosis and treatment. Researchers may be able to use FAM170B-AS1 as a diagnostic tool to identify early stages of cancer, or as a target for drugs that can inhibit FAM170B-AS1 activity.

In conclusion, the potential drug target and biomarker for FAM170B-AS1 is related to its function as a protein that is involved in various cellular processes, including cell signaling, cell adhesion, and cell migration. The discovery of FAM170B-AS1 as a potential drug target and biomarker for various diseases, including cancer, suggests that targeting FAM170B-AS1 may be a promising strategy for cancer treatment. Further research is needed to fully understand the role of FAM170B-AS1 as a drug target and biomarker.

Protein Name: FAM170B Antisense RNA 1

The "FAM170B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM170B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets